Meeting: 2017 ASCO Annual Meeting Track: Breast Cancer – Local/Regional/Adjuvant Abstract number: 501 Citation: J Clin Oncol 35, 2017 (suppl; abstr 501) Authors: Pier Franco Conte, Giancarlo Bisagni, Antonio Frassoldati, et al. Background: 1-year trastuzumab with chemotherapy is the standard adjuvant treatment for HER2+ breast cancer patients (pts). The efficacy...
Pro zobrazení tohoto obsahu je třeba být přihlášen.